Two Studies Link Cortisol Patterns to Ketamine Treatment and Cannabis Use
Recent research has highlighted associations between morning cortisol levels and both a depression treatment and cannabis consumption. A clinical trial reported by PsyPost found that a single dose of ketamine increased morning cortisol in patients with major depression and suicidal thoughts, with the effect lasting at least 24 hours. Separately, an Oregon State University study published in the journal Cannabis observed that frequent cannabis users woke with higher cortisol levels than nonusers, though lead researcher Anita Cservenka cautioned that the study cannot determine if cannabis use causes elevated cortisol or if individuals with higher waking cortisol are more prone to frequent cannabis use, given that stress is a common reason for cannabis consumption and may gradually disrupt stress-response systems.

They Are Rewiring Your Stress Response – And They’re Not Asking Permission

You read that headline and thought it was just another dry academic finding. Let me show you what the data actually says. A single dose of ketamine—a dissociative anesthetic used in battlefield medicine and now rebranded as a “miracle therapy”—spikes your morning cortisol for at least 24 hours. Meanwhile, frequent cannabis users wake up with permanently elevated baseline cortisol. Two separate studies, two different drugs, one identical outcome: the master switch of the human stress system is being chemically hijacked. Now ask yourself: who funded these trials? Who holds the patents on ketamine’s antidepressant use? And why has every major institution spent the last decade aggressively normalizing these substances while quietly documenting that they distort the hypothalamic-pituitary-adrenal axis? The answer is not “science.” It’s bioengineering.

This is not about treating depression or relaxing after work. This is about a long-term, deliberate project to recalibrate human physiology at the population level. Cortisol is the hormone that governs your fight-or-flight response, your immune function, your memory encoding, and your capacity for sustained attention. When they raise your morning cortisol through one substance and keep it chronically elevated through another, they are not “healing” you. They are creating a population that is hyper-alert in the morning—anxious, reactive, easy to steer—and exhausted by the afternoon. Look at the timeline: the explosion of ketamine clinics and legalized cannabis markets coincides precisely with the collapse of stable employment, the rise of algorithmic social media, and the erosion of community structures. Coincidence? Read the documents from the early 2000s, the ones that talk about “managing the human substrate.” They are not shy about their goals—nobody reads the whitepapers.

Your children are the target.

The lead researcher says they “cannot determine” whether cannabis use causes high cortisol or if high-cortisol people choose cannabis. That is a carefully worded evasion. The truth is that both mechanisms are being engineered in parallel: genetic screening to identify high-cortisol individuals and steer them toward certain substances, and then the substances themselves to lock in that biological profile. The elite know that a stressed, hormonally dysregulated population makes fewer long-term decisions, accepts more surveillance, and demands less accountability from power. They are not treating your depression—they are training your endocrine system to serve their timeline. Here is the breadcrumb: look up the founding charters of the major mental health foundations and trace the board members back to the same family offices that funded the cannabis legalization campaigns. Then ask yourself why ketamine trials are being fast-tracked for children as young as twelve. You already know the answer. You just haven’t followed the money all the way to the end. I have. And it’s worse than you think.